CytomX to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., March 01, 2018 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today announced that the company’s management will participate in two upcoming investor conferences. 

  • Sean McCarthy, D. Phil., president and chief executive officer, will present at the Cowen and Company 38th Annual Healthcare Conference on March 13, 2018, at 10:00 a.m. ET.
  • Debanjan Ray, Chief Financial Officer and Head of Corporate Development, will present at the Barclay’s Global Health Conference on March 15, 2018, at 8:30 a.m. ET.

A live audio webcast for each event will be available through the Investors and News section of CytomX’s website. An archived replay will be available for 90 days following the event.

About CytomX Therapeutics
CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of investigational Probody™ therapeutics. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company’s pipeline includes cancer immunotherapies against clinically-validated targets, such as CX-072, a PD-L1-targeting Probody therapeutic and BMS-986249, a CTLA-4-targeting Probody therapeutic, and first-in-class Probody drug conjugates against highly attractive targets, such as CX-2009, a CD166-targeting Probody drug conjugate and CX-2029, a CD71-targeting Probody drug conjugate, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company, Pfizer and ImmunoGen, Inc. For more information, visit or follow us on Twitter.

CytomX Therapeutics
Christine Quern

Trout Group
Pete Rahmer 



You May Also Like

NeuroMetrix Reports Publication of New Clinical Study on Quell Wearable Pain Relief Technology

WALTHAM, Mass., Oct. 02, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported publication ...

Morphotek and AREVA Med to collaborate on Lead-212 Targeted Alpha Therapies

EXTON, Pa. and COURBEVOIE, France, March 31, 2016 (GLOBE NEWSWIRE) -- Morphotek®, Inc., a ...

AnaptysBio Announces Appointment of J. Anthony Ware, M.D. to Board of Directors

SAN DIEGO, Aug. 24, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology ...